BACKGROUND: The use of beta-blockers in hypertrophic obstructive cardiomyopathy (HOCM) patients after alcohol septal ablation (ASA) lacks data support. We aimed to evaluate the effect of metoprolol on exercise capacity, hemodynamic and laboratory parameters, and quality of life in HOCM patients after ASA. METHODS: This was a prospective randomized single-center open-label crossover trial in 21 HOCM patients after ASA. Patients received metoprolol and no beta-blocker for two periods of three months. The endpoints were: peak oxygen uptake (pVO2), maximal left ventricular outflow tract (LVOT) pressure gradient at peak exercise, a ratio of mitral peak velocity of the early filling (E) to early diastolic mitral annular velocity (e') (E/e') at rest, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plasmatic concentration. RESULTS: No significant association was found between the treatment and any of the endpoints in the assessed patients: 1) pVO2 (19.5 ± 5.3 ml/kg/min vs. 19.4 ± 4.1 ml/kg/min, p = 0.90), 2) exercise-induced pressure gradient in LVOT 32 ± 37 mmHg vs. 32 ± 30 mmHg, p = 0.84, 3) E/e' ratio at rest (11 ± 4 vs. 10 ± 4, p = 0.23), 4) KCCQ overall summary score (78 ± 11 vs. 77 te ± 15, p = 0.56), 5) NT-proBNP (215 pg/ml [121-333] vs. 153 pg/ml [102-228], p = 0.19). CONCLUSIONS: In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.

Department of Cardiology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

See more in PubMed

Fifer M.A., Vlahakes G.J. Management of symptoms in hypertrophic cardiomyopathy. Circulation. 2008;117:429–439. PubMed

Sorajja P., Nishimura R.A., Gersh B.J., et al. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:234–241. PubMed

Arbelo E., Protonotarios A., Gimeno J.R., et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC) Eur Heart J. 2023;00:1–124.

Cohen L.S., Braunwald E. Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta-Adrenergic Blockade. Circulation. 1967;35:847–851. PubMed

Adelman A.G., Shah P.M., Gramiak R., Wigle E.D. Long-term propranolol therapy in muscular subaortic stenosis. Heart. 1970;32:804–811. PubMed PMC

Nistri S., Olivotto I., Maron M.S., et al. β Blockers for Prevention of Exercise-Induced Left Ventricular Outflow Tract Obstruction in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2012;110(5):715–719. PubMed

Dybro A., Rasmussen T.B., Nielsen R., Andersen M.J., Jensen M.K., Poulsen S.H. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78:2505–2517. PubMed

Ammirati E., Contri R., Coppini R., Cecchi F., Frigerio M., Olivotto I. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18(9):1106–1118. PubMed

Ommen S.R., Mital S., Burke M.A., et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: Executive Summary. J Am Coll Cardiol. 2020;76:3022–3055. PubMed

Rosing D.R., Condit J., Maron B.J., et al. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol. 1981;48:545–553. PubMed

Toshima H., Koga Y., Nagata H., Toyomasu K., Itaya K., Matoba T. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-Blind Crossover Study. Jpn Heart J. 1986;27:701–715. PubMed

Udelson J.E., Bonow R.O., O’Gara P.T., et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79:1052–1060. PubMed

Bourmayan C., Razavi A.N.E., Fournier C., et al. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: An echographic study. Am Heart J. 1985;109:1311–1316. PubMed

Alvares R.F., Goodwin J.F. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. Heart. 1982;48:204–212. PubMed PMC

Desai M.Y., Owens A.T., Geske J.B., et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80:95–108. PubMed

Olivotto I., Oręziak A., Barriales-Villa R., et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759–769. PubMed

Ho C.Y., Mealiffe M.E., Bach R.G., et al. Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75:2649–2660. PubMed

Bonaventura J. Rediscovering therapies for hypertrophic cardiomyopathy. Int J Cardiol. 2023;370:319–320. PubMed

Nagueh S.F., Groves B.M., Schwartz L., et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2011;58:2322–2328. PubMed

Veselka J., Jensen M.K., Liebregts M., et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37:1517–1523. PubMed